[1] |
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR[J]. N Engl J Med, 2021, 385(23):2150-2160.
|
[2] |
Guimarães HP, Lopes RD, de Barros E Silva P, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve[J]. N Engl J Med, 2020, 383(22):2117-2126.
|
[3] |
Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for atrial fibrillation in the older population: a randomized clinical trial[J]. JAMA Cardiol, 2021, 6(5):558-567.
|
[4] |
Albert CM, Cook NR, Pester J, et al. Effect of marine Omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial[J]. JAMA, 2021, 325(11):1061-1073.
|
[5] |
Nissen SE, Lincoff AM, Wolski K, et al. Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial[J]. JAMA Cardiol, 2021, 6(8):910-917.
|
[6] |
Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial[J]. Circulation, 2021, 143(18):1754-1762.
|
[7] |
Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial[J]. Circulation, 2021, 144(19):1543-1552.
|
[8] |
Darden D, Duong T, Du C, et al. Sex differences in procedural outcomes among patients undergoing left atrial appendage occlusion: insights from the NCDR LAAO registry[J]. JAMA Cardiol, 2021, 6(11):1275-1284.
|
[9] |
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation[J]. N Engl J Med, 2021, 384(4):305-315.
|
[10] |
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation[J]. N Engl J Med, 2021, 384(4):316-324.
|
[11] |
Turagam MK, Musikantow D, Whang W, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a Meta-analysis of randomized clinical trials[J]. JAMA Cardiol, 2021, 6(6):697-705.
|
[12] |
Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II[J]. JACC Clin Electrophysiol, 2021, 7(5):614-627.
|
[13] |
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med, 2018, 378(5):417-427.
|
[14] |
Brachmann J, Sohns C, Andresen D, et al. Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF trial[J]. JACC Clin Electrophysiol, 2021, 7(5):594-603.
|
[15] |
Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure[J]. Circulation, 2021, 144(11):845-858.
|
[16] |
Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial[J]. Circulation, 2021, 143(14):1377-1390.
|
[17] |
Vinther M, Risum N, Svendsen JH, et al. A randomized trial of His pacing versus biventricular pacing in symptomatic HF patients with left bundle branch block (His-Alternative)[J]. JACC Clin Electrophysiol, 2021, 7(11):1422-1432.
|
[18] |
Hughes JW, Olgin JE, Avram R, et al. Performance of a convolutional neural network and explainability technique for 12-Lead electrocardiogram interpretation[J]. JAMA Cardiol, 2021, 6(11):1285-1295.
|
[19] |
Raghunath S, Pfeifer JM, Ulloa-Cerna AE, et al. Deep neural networks can predict new-onset atrial fibrillation from the 12-lead ECG and help identify those at risk of atrial fibrillation-related stroke[J]. Circulation, 2021, 143(13):1287-1298.
|
[20] |
Mittal S, Oliveros S, Li J, et al. AI filter improves positive predictive value of atrial fibrillation detection by an implantable loop recorder[J]. JACC Clin Electrophysiol, 2021, 7(8):965-975.
|
[21] |
Bos JM, Attia ZI, Albert DE, et al. Use of Artificial intelligence and deep neural networks in evaluation of patients with electrocardiographically concealed long QT syndrome from the surface 12-lead electrocardiogram[J]. JAMA Cardiol, 2021, 6(5):532-538.
|